Indian Institute of Technology Bombay
The engineering institute whose bioscience department, with Tata Memorial, built India's first home-grown CAR-T cell therapy and spun it out as ImmunoACT.
Overview
IIT Bombay, founded in 1958 on a 545-acre campus at Powai, is one of India's leading technical universities. Its Department of Biosciences and Bioengineering hosts the laboratory of Rahul Purwar, where research on a humanised CD19 CAR-T construct began in 2013; the programme partnered with Tata Memorial Centre and ACTREC for clinical development, was spun out as ImmunoACT in 2018, dosed its first patients at Tata Memorial Hospital in 2021 and won India's first CAR-T approval (NexCAR19, talicabtagene autoleucel) in 2023. The institute also works on cancer imaging, medical devices and computational biology.
- Biosciences and Bioengineering (CAR-T origin)
- Medical devices and imaging
- Digital health
Pages like this
not linked directly; found by shared links- PersonHasmukh Jain
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
- PersonGaurav Narula
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Talicabtagene autoleucel, Tata Memorial Centre, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
- CompanyCipla
Shares ImmunoACT, Talicabtagene autoleucel, Most of the world has almost no cancer care, CAR-T cell therapy.
- ProductVarnimcabtagene autoleucel
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, CD19, Manufacturing cost and time for living and radioactive medicines.
- CompanyImmuneel Therapeutics
Shares Point-of-care and decentralised cell manufacturing, CD19, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, CAR-T cell therapy.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares CD19, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.